Analysts Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) PT at $65.00

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) has been assigned an average recommendation of "Buy" from the seven ratings firms that are covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $65.00.

Several research analysts have recently issued reports on ARCT shares. HC Wainwright reiterated a "buy" rating and issued a $63.00 price objective on shares of Arcturus Therapeutics in a report on Friday. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arcturus Therapeutics in a report on Monday, December 16th. Finally, BTIG Research started coverage on shares of Arcturus Therapeutics in a report on Tuesday, January 28th. They issued a "buy" rating and a $41.00 price objective for the company.

Arcturus Therapeutics Stock Performance

Shares of NASDAQ:ARCT traded up $1.64 during trading hours on Thursday, hitting $18.05. The stock had a trading volume of 842,108 shares, compared to its average volume of 362,393. The stock's fifty day simple moving average is $17.01 and its 200 day simple moving average is $18.95. The firm has a market capitalization of $488.97 million, a price-to-earnings ratio of -8.13 and a beta of 2.62. Arcturus Therapeutics has a 1-year low of $14.30 and a 1-year high of $45.00.

Institutional Trading of Arcturus Therapeutics

Large investors have recently added to or reduced their stakes in the business. nVerses Capital LLC bought a new stake in Arcturus Therapeutics during the third quarter worth approximately $42,000. Virtus ETF Advisers LLC boosted its holdings in Arcturus Therapeutics by 38.8% during the fourth quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company's stock worth $69,000 after buying an additional 1,132 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Arcturus Therapeutics in the 4th quarter valued at approximately $71,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Arcturus Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company's stock valued at $121,000 after acquiring an additional 2,038 shares in the last quarter. Finally, National Bank of Canada FI lifted its position in shares of Arcturus Therapeutics by 639.6% in the 4th quarter. National Bank of Canada FI now owns 5,532 shares of the biotechnology company's stock valued at $94,000 after acquiring an additional 4,784 shares in the last quarter. 94.54% of the stock is currently owned by institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.